Fredrik Jarrsten - Orexo AB Ex CFO
| ORXOF Stock | USD 1.08 0.00 0.00% |
Insider
Fredrik Jarrsten is Ex CFO of Orexo AB
| Age | 56 |
| Phone | 46 1 87 80 88 00 |
| Web | https://www.orexo.com |
Orexo AB Management Efficiency
The company has return on total asset (ROA) of (0.0965) % which means that it has lost $0.0965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6535) %, meaning that it generated substantial loss on money invested by shareholders. Orexo AB's management efficiency ratios could be used to measure how well Orexo AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sibyl Swift | cbdMD Inc | 43 | |
| Matthew Coapman | cbdMD Inc | 48 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Kevin MacDermott | cbdMD Inc | 62 | |
| Hermann Lubbert | Biofrontera | 68 | |
| Mark Baldyga | Biofrontera | N/A | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| David Erickson | Evolus Inc | N/A | |
| Sandra Beaver | Evolus Inc | 46 | |
| BCom BAcc | Akanda Corp | 44 | |
| Amos Cohen | INC Research Holdings | 45 | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| Thomas Flow | Akanda Corp | 46 | |
| Erica CPA | Biofrontera | 39 | |
| OriMoni Mimon | INC Research Holdings | 36 | |
| Jeff Holm | Biofrontera | N/A | |
| Rami Levy | INC Research Holdings | 59 | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| Tejinder Virk | Akanda Corp | 42 | |
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| Eugene III | Biofrontera | 39 | |
Management Performance
| Return On Equity | -0.65 | |||
| Return On Asset | -0.0965 |
Orexo AB Leadership Team
Elected by the shareholders, the Orexo AB's board of directors comprises two types of representatives: Orexo AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orexo. The board's role is to monitor Orexo AB's management team and ensure that shareholders' interests are well served. Orexo AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orexo AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fredrik Jarrsten, Ex CFO | ||
| MD MBA, Chief Officer | ||
| Cecilia Coupland, VP Operations | ||
| Nikolaj Sorensen, Pres CEO | ||
| Lena Wange, Investor Relations & Communications Manager | ||
| Jesper Lind, Advisor | ||
| Dennis Urbaniak, Ex Therapeutics | ||
| Robert DeLuca, President of Orexo US Inc. | ||
| Robert Ronn, VP RD |
Orexo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Orexo AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | |||
| Return On Asset | -0.0965 | |||
| Profit Margin | (0.28) % | |||
| Current Valuation | 76.98 M | |||
| Shares Outstanding | 34.35 M | |||
| Shares Owned By Insiders | 17.29 % | |||
| Shares Owned By Institutions | 42.78 % | |||
| Price To Earning | 58.66 X | |||
| Price To Book | 2.02 X | |||
| Price To Sales | 0.99 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Orexo OTC Stock
Orexo AB financial ratios help investors to determine whether Orexo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orexo with respect to the benefits of owning Orexo AB security.